Ajanta Pharma
Ajanta Pharma Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Ajanta Pharma Limited, framed against the sector median so the premium or discount is obvious at a glance.
Ajanta Pharma Limited trades at a P/E of 38.51× and P/B of 8.98×.
Valuation
Profitability
Growth
Financial Health
Ajanta Pharma Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Ajanta Pharma Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Ajanta Pharma Limited financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Ajanta Pharma Limited, switchable between annual and quarterly views, consolidated or standalone.
Ajanta Pharma Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹4,06,75,29,11,056.8 Cr and reported EPS of ₹84.47.
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 2,131 | 2,055 | 2,588 | 2,890 | 3,341 | 3,743 | 4,209 | 4,648 | 5,453 |
| Other Income | 24 | 21 | 92 | 26 | 116 | 99 | 85 | 95 | 172 |
| Total Income | 2,155 | 2,076 | 2,680 | 2,916 | 3,457 | 3,841 | 4,293 | 4,743 | 5,625 |
| Cost of Goods Sold (COGS) | 406 | 383 | 656 | 645 | 832 | 1,050 | 1,067 | 1,071 | 1,184 |
| Gross Profit | 1,724 | 1,672 | 1,932 | 2,245 | 2,509 | 2,692 | 3,142 | 3,577 | 4,269 |
| +Operating Expenses | 1,066 | 1,105 | 1,249 | 1,246 | 1,579 | 1,909 | 1,970 | 2,318 | 2,874 |
| EBITDA | 658 | 566 | 683 | 999 | 929 | 783 | 1,172 | 1,260 | 1,395 |
| +Non-Operating Expenses | 60 | 73 | 104 | 124 | 136 | 137 | 143 | 165 | 189 |
| Profit Before Tax (PBT) | 623 | 514 | 664 | 900 | 909 | 745 | 1,114 | 1,189 | 1,378 |
| +Tax Expense | 154 | 127 | 196 | 246 | 197 | 157 | 298 | 269 | 322 |
| Total Profit for Period | 469 | 387 | 468 | 654 | 713 | 588 | 816 | 920 | 1,056 |
| Net Profit (Owner's PAT) | 469 | 387 | 468 | 654 | 713 | 588 | 816 | 920 | 1,056 |
| Earnings Per Share (EPS) | 35.50 | 29.57 | 35.73 | 50.38 | 55.62 | 45.89 | 64.82 | 73.68 | 84.52 |
| Diluted Shares Outstanding (Nos.) | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 12 | 12 |
| +Additional Disclosures | 1,943 | 1,942 | 2,673 | 2,654 | 3,371 | 4,161 | 4,247 | 4,626 | 5,460 |
| Sales Growth % | — | -3.54 | 25.91 | 11.66 | 15.62 | 12.02 | 12.45 | 10.44 | 17.31 |
| YoY Sales Growth % | — | -3.54 | 25.91 | 11.66 | 15.62 | 12.02 | 12.45 | 10.44 | 17.31 |
| Material Cost % | 18 | 19 | 22 | 24 | 23 | 23 | 22 | 18 | 17 |
| Employee Cost % | 18 | 21 | 19 | 19 | 19 | 21 | 21 | 23 | 24 |
| Other Cost % | 32 | 33 | 29 | 24 | 28 | 30 | 25 | 26 | 29 |
| OPM % | 31 | 28 | 26 | 35 | 28 | 21 | 28 | 27 | 26 |
| Tax % | 25 | 25 | 30 | 27 | 22 | 21 | 27 | 23 | 23 |
| Profit Growth % | — | -17.43 | 20.86 | 39.81 | 8.99 | -17.50 | 38.81 | 12.77 | 14.73 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| +Additional Fields | 599 | 494 | 588 | 882 | 804 | 652 | 1,037 | 1,115 | 1,222 |
Ajanta Pharma segment analysis: revenue and profit mix.
Disclosed business segments at Ajanta Pharma with their share of revenue and profit, switchable between consolidated and standalone reporting.
Ajanta Pharma discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Ajanta Pharma Limited.
Our AI distills the core fundamental drivers supporting Ajanta Pharma Limited, the risks that threaten it, and the exact valuation or growth triggers that should make you re-evaluate.
Ajanta Pharma Limited's investment case rests on 10 positive markers and 7 flagged concerns drawn from the latest reported filings.
What you're getting.
High Return on Capital Employed (ROCE 32.40%) indicates efficient capital utilization.
Minimal debt-to-equity ratio (0.01) provides strong financial stability and low risk.
Consistent 5-year FOCF CAGR (31.02%) demonstrates robust cash flow generation.
Strong 52-week stock return (58.39%) reflects positive investor sentiment and momentum.
Substantial promoter holding (66.2%) aligns management interests with shareholder value.
What can break it.
Elevated P/E ratio (34.23) suggests potential overvaluation compared to earnings.
P/E ratio (32.90) is higher than key peers, limiting upside potential.
Promoter holding decreased (70.48% to 66.26%) over two years, warrants monitoring.
Quarterly profit growth (3.89%) lags significantly behind robust quarterly sales.
Recent stock price volatility observed between 52-week high (₹3115.90) and low (₹2327.30).
What would change my mind.
Trim if P/E re-rates above 50. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 20%. The operating engine is no longer compounding capital efficiently.
Ajanta Pharma Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Ajanta Pharma Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
Ajanta Pharma Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Ajanta Pharma Limited — derived from the live tape, not yesterday's close.
Ajanta Pharma Limited last traded at ₹3,255.7 with an intraday range of ₹3,167.7–₹3,265 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹3255.70| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 3485.83 | +230.13 | +7.07% |
| R3 | 3388.53 | +132.83 | +4.08% |
| R2 | 3326.77 | +71.07 | +2.18% |
| R1 | 3291.23 | +35.53 | +1.09% |
| PIVOT | 3229.47 | -26.23 | -0.81% |
| CURRENT | 3255.70 | — | — |
| S1 | 2999.33 | -256.37 | -7.87% |
| S2 | 3096.63 | -159.07 | -4.89% |
| S3 | 3132.17 | -123.53 | -3.79% |
| S4 | 3193.93 | -61.77 | -1.90% |
AJANTPHARM is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 3167.7 ~ 3235
Trading Inside opening range
Ajanta Pharma Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Ajanta Pharma Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Ajanta Pharma Limited stood at 51.0% of traded volume, against a 20-day average of 51.7%.
Ajanta Pharma announcements: results, concalls, ratings, M&A.
Filings Ajanta Pharma sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Ajanta Pharma files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 88 documents below.
Copy of Newspaper Publication
Ajanta Pharma Limited has informed the Exchange about Copy of Newspaper Publication
Shareholders meeting
Ajanta Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 16, 2026
Copy of Newspaper Publication
Ajanta Pharma Limited has informed the Exchange about Copy of Newspaper Publication
General Updates
Ajanta Pharma Limited has informed the Exchange about Shareholders Meeting- 47th Annual General Meeting on 16/07/2026
Analysts/Institutional Investor Meet/Con. Call Updates
Ajanta Pharma Limited has informed the Exchange about Participation in Investor Conference
Ajanta Pharma insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Ajanta Pharma as reported to SEBI — buying and selling signals from the people who know the business best.
Ajanta Pharma insider activity below tracks 7 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| SHAILESH R SINGH | Insider | 12 Mar 2026 | buy | +607 | ₹18.82 L | ₹3,100.18 |
| SHAILESH R SINGH | Insider | 12 Mar 2026 | buy | +607 | ₹18.82 L | ₹3,100.18 |
| SHAILESH R SINGH | Insider | 12 Mar 2026 | buy | +607 | ₹18.82 L | ₹3,100.18 |
| VANDANA SHAILESH SINGH | Insider | 27 Feb 2025 | sell | −548 | ₹14.92 L | ₹2,722.45 |
| J K TRIPATHI | Insider | 30 Dec 2024 | sell | −100 | ₹2.95 L | ₹2,950.00 |
| J K TRIPATHI | Insider | 18 Dec 2024 | sell | −100 | ₹2.9 L | ₹2,895.00 |
| J K TRIPATHI | Insider | 29 Nov 2024 | sell | −100 | ₹3 L | ₹3,000.00 |
Ajanta Pharma dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Ajanta Pharma has declared, sequenced by announce and record date.
Ajanta Pharma corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Ajanta Pharma Limited: business, sector, key facts.
What Ajanta Pharma Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Ajanta Pharma Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: AJANTPHARM, BSE: 532331.
Ajanta Pharma Limited is a pharmaceutical company specializing in the development, manufacturing, and marketing of finished dosage forms of specialty pharmaceuticals. Their product portfolio encompasses both chronic and acute therapies, primarily focusing on branded generic medications. This means they produce medications similar to brand-name drugs once their patents expire, but under their own branding, allowing them to offer more affordable options to consumers.
The company's manufacturing capabilities are diverse, covering a wide range of dosage forms. These include common formats like tablets and capsules, but also extend to more specialized delivery methods such as injectables, inhalers, and topical applications in the form of ointments, creams, and liquids. This broad range of delivery methods allows Ajanta Pharma to cater to a wide variety of medical needs and patient preferences.
Ajanta Pharma's therapeutic focus spans several key areas of healthcare. Their products address conditions related to cardiology (heart health), dermatology (skin conditions), ophthalmology (eye care), and pain management. This strategic focus on specific therapeutic areas allows them to develop expertise and build a strong reputation within those markets.
The company maintains a significant global presence, operating across multiple continents. Their markets include India, where they are headquartered, as well as extensive operations in Africa and Asia. Furthermore, they have established a presence in the United States, a major pharmaceutical market, demonstrating a commitment to international expansion and a broad reach within the global healthcare landscape.
Founded in 1973 and headquartered in Mumbai, India, Ajanta Pharma has a long history in the pharmaceutical industry. Their continued success is likely driven by their diverse product portfolio, comprehensive manufacturing capabilities, focus on key therapeutic areas, and significant global reach. The company's commitment to producing high-quality, affordable medications suggests a continued focus on providing access to essential healthcare worldwide.
Questions investors ask about Ajanta Pharma Limited (AJANTPHARM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Ajanta Pharma Limited (AJANTPHARM)?
The current share price of Ajanta Pharma Limited (AJANTPHARM) is ₹3,255.7. Today, the stock has gained by ₹68.30 (2.14%), trading in a range of ₹3,167.7 to ₹3,265. The stock opened at ₹3,185 with a trading volume of 88,002 shares.
02Is Ajanta Pharma Limited stock a good investment for long-term?
Ajanta Pharma Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹4,06,75,29,11,056.8 crores, P/E ratio of 38.51, ROE of 25.39%, and ROCE of 32.40%. The dividend yield stands at 0.86%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Ajanta Pharma Limited stock?
The 52-week high price of Ajanta Pharma Limited (AJANTPHARM) is ₹3,314.9, while the 52-week low is ₹2,329.9. Currently trading at ₹3,255.7, the stock is 94.0% away from its 52-week low and 1.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Ajanta Pharma Limited stock at the current price?
Whether to buy Ajanta Pharma Limited stock at ₹3,255.7 depends on multiple factors. The stock is currently trading with a P/E ratio of 38.51 and P/B ratio of 8.98. Today's performance shows a gain of 2.14%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Ajanta Pharma Limited and when is the next dividend?
Ajanta Pharma Limited offers a dividend yield of 0.86%, which means for every ₹100 invested at the current price of ₹3,255.7, you can expect to receive approximately ₹0.86 annually as dividends. The face value of the stock is ₹0.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Ajanta Pharma Limited?
Ajanta Pharma Limited's key financial metrics include: P/E Ratio: 38.51, P/B Ratio: 8.98, ROE: 25.39%, ROCE: 32.40%, Dividend Yield: 0.86%, EPS: ₹84.47, Book Value: ₹362.41, and Debt-to-Equity: 0.06. The company's market cap stands at ₹4,06,75,29,11,056.8 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Ajanta Pharma Limited stock performing today in the market?
Ajanta Pharma Limited stock opened at ₹3,185 and is currently trading at ₹3,255.7, showing a gain of ₹68.30 (2.14%). The intraday high is ₹3,265 and low is ₹3,167.7. The trading volume stands at 88,002 shares, indicating moderate market participation today.
08What is the P/E ratio of Ajanta Pharma Limited and what does it indicate?
Ajanta Pharma Limited has a Price-to-Earnings (P/E) ratio of 38.51, which means investors are willing to pay ₹38.51 for every ₹1 of earnings. With an EPS of ₹84.47, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Ajanta Pharma Limited (AJANTPHARM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Albert David (ALBERTDAVD) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Top quality scorecard stocksScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy